). Other types of variations, where present, are indicated below the maps Variation is shown by capital letters this study, which was approved by the ethical committee of the RIKEN SNP Research Center. The SNP screening methods described in an earlier report by Haga et al. (2002) were the principal techniques used in this study. In brief, on the basis of genomic sequences from the GenBank database in the US National Center for Biotechnology Information (NCBI), we designed primers to amplify all selected genes in their entirety, excluding only regions that corresponded to repetitive sequences predicted by the RepeatMasker program (http://repeatmasker.genome.washington.edu/ cgi-bin/RepeatMasker). Each polymerase chain reaction (PCR) was performed with 20 ng of mixed genomic DNA derived from three individuals. All 16 mixed samples were amplified in the GeneAmp PCR system 9700 (PE Applied Biosystems, Foster City, CA, USA) under the following conditions: initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 2 min, and post-extension at 72°C for 7 min. Products obtained from the PCR experiments served as templates for direct sequencing and detection of SNPs, using the fluorescent dye-terminator cycle-sequencing method. All SNPs detected by the Polyphred computer program (Nickerson et al. 1997) were confirmed by sequencing both strands of each PCR product.
Accession numbers of the genomic sequences we obtained for this study are as follows: beta-1 adrenergic AC008569.6), prostaglandin E receptor 2 (PTGER2; AL365475.1), prostaglandin F receptor (PTGFR; AL136324.6), thromboxane A2 receptor (TBXA2R; AC005175.1), and vascular cell adhesion molecule 1 (VCAM1; AL157715.5).
Results and discussion
By direct sequencing of DNA from 48 healthy individuals, we screened SNPs in a total of approximately 382 kb of genomic DNA that accounted for 60% of the 638 kilobases encompassing the loci of 31 selected genes, minus repetitive sequences. We identified a total of 781 variations, including 668 SNPs and 113 variations of other types, and constructed a fine-scale SNP map of each locus (Fig. 1) . Detailed information for each variation identified in this study is summarized in Table 1 . Regional distributions of the SNPs identified among the 31 loci were as follows: 86 in 5Ј flanking regions, 27 in 5Ј untranslated regions, 45 in coding regions, 399 in introns, 47 in 3Ј un-translated regions, and 64 in 3Ј flanking regions ( Table 2 ). The 86 SNPs present in 5Ј flanking regions (putative promoter regions) could affect the quantity of the respective gene products. Moreover, among the 45 SNPs found in coding regions, 15 were nonsynonymous changes; although the minor-allele frequencies of these 15 SNPs were as low as 2.2%, it should be emphasized that such alterations are likely to influence functions and/or structures of proteins. The overall frequencies of nucleotide substitutions in our test population (96 chromosomes) were counted as 36.8% for A/G, 36.4% for C/T, 8.2% for C/G, 7% for T/G, 6.3% for A/C, and 5.2% for A/T; transitions occurred 2.7 times more frequently than transversions (Table 3 ). The overall genomic distribution was 1/572 bp in the 382 kb of DNA that we sequenced. By comparing our data with earlier reports from elsewhere (Unoki et al. 2000; Muldoon et al. 2001; Okuda et al. 2002) and with the dbSNP datebase at NCBI, we were able to consider 371 of the 668 SNPs (55.5%) to be novel as of the middle of August 2002.
The 668 SNPs identified here provide genetic data that should be helpful for designing personalized medical care and also for identifying genes associated with drug efficacy and/or adverse drug reactions.
